Esketamine Formulation Light-Excluded Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical compositions containing esketamine for treating treatment-resistant depression face challenges in maintaining precise amounts of esketamine and minimizing oxidative degradation products, such as 6-(2-chlorophenyl)-6-oxohexanoic acid, which affect efficacy and safety.
Innovation Solution
The development of pharmaceutical compositions comprising esketamine with controlled levels of oxidative degradants, specifically not more than 0.2% (HPLC area) of 6-(2-chlorophenyl)-6-oxohexanoic acid, and methods for preparing and storing these compositions in the absence of light to prevent degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If esketamine is stored in conventional conditions (exposed to light), then the formulation can be handled and administered, but oxidative degradation occurs forming harmful degradants such as 6-(2-chlorophenyl)-6-oxohexanoic acid
Solution Approach 1:
The patent applies preliminary anti-action by pre-preparing the esketamine formulation in the absence of light and minimizing light exposure during all handling steps. This preventive measure counteracts the oxidative degradation that would otherwise occur upon light exposure, thereby maintaining stability and preventing harmful degradant formation before they can occur
Solution Approach 2:
The patent creates an inert environment by conducting all preparation and handling operations in the absence of light. This light-exclusion environment acts as a protective atmosphere that prevents photo-oxidation of esketamine, thereby maintaining drug stability and preventing the formation of oxidative degradants
2Object-generated harmful factors
If light exposure is minimized to prevent degradation, then oxidative degradant formation is reduced, but preparation and administration procedures become more complex
Solution Approach 1:
The patent applies preliminary action by preparing the entire esketamine formulation in the absence of light before administration. All critical steps including mixing, filling, and sealing are completed under light-excluded conditions in advance, so that the final product is already protected and requires minimal additional protective measures during storage and handling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures the maintenance of precise esketamine amounts and minimizes oxidative degradation, enhancing the safety and efficacy of esketamine formulations by reducing impurities and extending their stability during storage.
Implementation Method 1
pharmaceutical compositions comprising esketamine or a pharmaceutically acceptable salt thereof and an oxidative degradant
Implementation Method 2
storing the pharmaceutical composition in the absence of light; exposing the pharmaceutical composition to about 6 hours or less of light
Data Source
AI summary
The disclosure is directed to pharmaceutical compositions comprising esketamine or a pharmaceutically acceptable salt thereof and an oxidative degradant. In certain aspects, the oxidative degradant is 6-(2-chlorophenyl)-6-oxohexanoic acid or a pharmaceutically acceptable salt thereof. Methods for limiting the formation of oxidative degradants in a pharmaceutical composition comprising esketamine or a pharmaceutically acceptable salt thereof are also disclosed.